Clinical Trial Update: Sodium Butyrate For Improving Cognitive Function In Schizophrenia [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial evaluating sodium butyrate for improving cognitive function in schizophrenia has been withdrawn from Phase 2/Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Schizophrenia

Drugs mentioned

• Sodium butyrate (sodium butyrate)

Snippet

Sponsor: Shanghai Mental Health Center | Conditions: Schizophrenic Disorder, Cognitive Impairment | Phase 2, Phase 3 | Status: WITHDRAWN